Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02772679 · ClinicalTrials.gov registry record · Phase 1
T1DM Immunotherapy Using Polyclonal Tregs + IL-2
A Phase 1 study of Type 1 Diabetes Mellitus, sponsored by Jeffrey Bluestone.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT02772679: Completed Phase 1 study of Type 1 Diabetes Mellitus, sponsored by Jeffrey Bluestone.
NCT02772679 is a Phase 1 study of Type 1 Diabetes Mellitus that has completed, run by Jeffrey Bluestone. The registered enrollment target is 16 participants, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02772679, a Phase 1 study of Type 1 Diabetes Mellitus, has completed, sponsored by Jeffrey Bluestone.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess the safety of Tregs + IL-2 and survival of Tregs in patients with recent onset T1DM who receive infusions of autologous Tregs + IL-2.
Primary Outcome
Adverse events of special interest: including infections, malignancies, safety of Treg infusions, and local and systemic reactions to IL-2.
Conditions Studied
Interventions
- BIOLOGICAL PolyTregs+IL-2
Study Locations (2)
California
- University of California, San Francisco Medical Center - San Francisco
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-08 |
| Est. Completion | 2021-08-27 |
| Phase | Phase 1 |
What the finished NCT02772679 record still lists
NCT02772679 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which PolyTregs+IL-2 is the first listed.
NCT02772679 reports a single indexed study location in California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02772679 about?
NCT02772679 is a clinical study titled "T1DM Immunotherapy Using Polyclonal Tregs + IL-2". The purpose of this study is to assess the safety of Tregs + IL-2 and survival of Tregs in patients with recent onset T1DM who receive infusions of autologous Tregs + IL-2.
What is the current status of trial NCT02772679?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-08. Estimated completion is 2021-08-27.
What conditions does trial NCT02772679 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT02772679?
The interventions under investigation include: PolyTregs+IL-2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02772679?
This trial is sponsored by Jeffrey Bluestone, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02772679 being conducted?
This trial has 2 study locations across California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02772679's enrollment target sits among peer trials
16 97th of 112 higher than 12 of 112 other Type 1 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
RECRUITING · Phase 1
-
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
RECRUITING · Phase 1
-
An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia